Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04131829 · ClinicalTrials.gov registry record · Phase 1
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
A Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04131829: Recruiting Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Yale University.
NCT04131829 is a Phase 1 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 100 participants, below the 2,063-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04131829, a Phase 1 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed randomized, double-blind research study will use functional magnetic resonance neuroimaging using state-of-the-art HCP acquisition protocols and analytic pipelines, to identify predictors and correlates of response to an accepted first-line pharmacological treatment for obsessive-compulsive disorder.
Primary Outcome
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS);72,73 -This is a checklist and Clinician administered - 10 item severity scale, from none to extreme. Total severity score range is 0 to 40. This will be presented as % improvement in Y-BOCS as a continuous measure of treatment response, rather than an artificially dichotomized measure of 'response', in all analyses. This the primary outcome measure of change across the study treatment and scans.
Conditions Studied
Interventions
- DRUG Fluoxetine - immediate treatment
- DRUG Fluoxetine - delayed treatment
Study Locations (1)
Connecticut
- Yale OCD Research Clinic - CMHC/CNRU, 34 Park ST - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT04131829 shows while recruiting
NCT04131829 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,063-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Fluoxetine - immediate treatment is the first listed.
NCT04131829 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04131829 about?
NCT04131829 is a clinical study titled "Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD". The proposed randomized, double-blind research study will use functional magnetic resonance neuroimaging using state-of-the-art HCP acquisition protocols and analytic pipelines, to identify predictors and correlates of response to an accepted first-line pharmacological treatment for obsessive-compul...
What is the current status of trial NCT04131829?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2019-10-14. Estimated completion is 2026-12-31.
What conditions does trial NCT04131829 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT04131829?
The interventions under investigation include: Fluoxetine - immediate treatment (DRUG), Fluoxetine - delayed treatment (DRUG).
Who is sponsoring clinical trial NCT04131829?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04131829 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04131829's enrollment target sits among peer trials
100 31st of 84 higher than 52 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Study of RR-HNK in OCD
RECRUITING · Phase 1
-
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
RECRUITING · Phase 1
-
Effects of Repeated Psilocybin Dosing in OCD
ACTIVE NOT RECRUITING · Phase 1
-
Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 1
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI